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STRAKT
The purpose of the present study was to determine the correlations between the state of carbohydrate metabolism and concentrations of apelin in blood of patients with type 2 diabetes mellitus with 
different phenotypes. Materials and methods: a total of 32 patients with type 2 diabetes mellitus with 
different phenotypes (13 men, mean age 56,77 ± 1,79 years) were examined. The control group included 
20 healthy individuals. Results: the significant elevation of adipocytokine apelin level was found. The 
significant correlations between body mass index, apelin and the parameters of carbohydrate metabo­
lism were defined. Conclusions: the increased levels of apelin and connection between this adipocyto- 
kine and anthropometric parameters, as well as the indices of carbohydrate metabolism suggest that 
the elevated body weight contributes to activation and strengthening of impact mechanisms of adipose 
tissue hormones on metabolic status.
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НОТАЦИЯ
Цел ь и сследован и я -  изучение взаимосвязей между показателями углеводного обмена, концен­трациями апелина в плазме крови у больных сахарным диабетом типа 2 с различным фенотипом.
М а те р и а л ы  и  м ето д ы . Было обследовано 32 больных сахарным диабетом типа 2 с различ­
ным фенотипом (13 мужчин, средний возраст 56,77 ± 1,79 лет). Контрольную группу составили 20 
практически здоровых лиц.
Р е зу л ь та ты . Выявлены значимые повышения содержания этого адипоцитокина и наличие 
значимых корреляционных связей между индексом массы тела, апелином и показателями угле­
водного обмена.
В ы в о д ы . Повышенные уровни апелина в крови, а также связь этого адипоци-токина с ан­
тропометрическими показателями и показателями углеводного обме-на дает возможность пред­
положить, что при повышенной массе тела активируются и углубляются механизмы влияния 
гормонов жировой ткани на метаболический статус при сахарном диабете типа 2.
ю ч е в ы е  слова: сахарный диабет типа 2, апелин, ИМТ, повышенная масса тела.
Журавлева Л.В., 
Шеховцова Ю А .
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Obesity and metabolic syndrome (MS) are 
considered as a global epidemic of noninfectious 
genesis [2]. MS occurs in 17.9% of men up to 40 
years old and in 43.7% of men between 40 and 
55 years in Ukraine and Europe. The incidence 
of MS is much lower in women and occurs in 
7.1% up to 40 years and in 19.9% aged from 40 
to 55 years [1].
MS is a cluster of disorders such as 
insulin resistance (IR), dyslipidemia, visceral 
(abdominal) obesity, hyperinsulinemia, arterial 
hypertension, impaired glucose tolerance and 
type 2 diabetes mellitus (T2DM), nonalcoholic 
fatty liver disease and other.
It is known, that adipose tissue is an endocrine 
organ that consists of certain cells -  adipocytes 
that produce the hormone-like substances -  
adypocytokines. The main physiological role of 
adypocytokines is the storage of triacylglycerols 
during the periods of excess calorie intake and 
mobilization of this reserve in those periods 
when expenses exceed the supply. The regulation 
of these processes in adipose tissue is under the 
direct influence of hormones, cytokines and 
other factors that are involved in the metabolism 
of energy [3].
According to current data, a lot of the signal 
substances are synthesized in the white adipose 
tissue, including leptin, TNF-a [7], interleukin-6 
(IL-6), interleukin-8 [7] and the corresponding 
soluble receptors. The number of newly 
discovered substances, which are secreted by 
adipocytes, is constantly increasing and includes 
angiotensinogen, angiotensin II, plasminogen 
activator inhibitor-1 (PAI-1), adiponectin, apelin.
It should be noted that inflammatory changes 
depend on location of the adipose tissue. The 
concentration of some adypocytokines and 
the activity of some enzymes in visceral fat is 
higher than in the subcutaneous adipose tissue. 
The production of PAI-1, angiotensinogen, 
IL-6 dominates in visceral fat (compared to 
subcutaneous adipose tissue). Besides, the higher 
ratio of androgens/estrogens and a greater 
activity of 17-hydroxysteryddehydrogenase is 
more common for visceral fat. The production 
of adiponectin and leptin, the higher activity of 
aromatase prevails in the subcutaneous adipose 
tissue compared to visceral fat.
The increase of volume of visceral adipose 
tissue leads to the systemic release of resistin
and proatherogenic interleukin. The increased 
levels of circulating cytokines are associated 
with the development of IR in muscle tissue. 
The study which investigated the distribution of 
adipose tissue (according to magnetic resonance 
imaging) and functions of microvasculature 
(by videomicroscope) found that inflammatory 
condition of the body is associated with visceral 
obesity and depletions of the microvasculature
[4].
Thus, white adipose tissue is in the center of 
the system of autocrine, paracrine and endocrine 
signaling substances. There are several evidences 
that deregulation of the synthesis and secretion 
of adypocytokines impacts the development of 
metabolic diseases such as MS, T2DM. Thus, 
adypocytokines can serve as a link through which 
obesity and IR become risk factors for T2DM.
The pathological relationship between 
obesity and T2DM is confirmed by many studies. 
The 9-fold increased risk of T2DM in men with 
a body mass index over 30 kg / m2 demonstrates 
this relationship particularly evidently [4]. 
Approximately 80% of patients with T2DM have 
abdominal obesity [4]. The particular importance 
in the development of these pathologies is given 
to the metabolic disorders.
Along with the known pathogenetic aspects 
of T2DM, there are several factors that have been 
insufficiently studied, among them -  the effects 
of hormones of adipose tissue (adypocytokines).
Apelin is an adypocytokine, known for its 
ability to influence the metabolism. Several 
studies have shown that apelin is secreted by 
adipose tissue cells of mice and humans [3]. 
It has been proven that high levels of apelin in 
plasma and its increased expression by adipose 
tissue have been determined in laboratory 
animals with obesity, hyperinsulinemia and 
hyperglycemia, as well as in persons with obesity 
and hyperinsulinemia and / or with T2DM.
Therefore, the promising area of research 
is to investigate the role of adypocytokines in 
the pathogenesis of obesity and T2DM. Timely 
detection of these disorders contributes to 
improving the results of diagnosis of this disease, 
especially in the presence of increased body 
weight.
T h e  p u rp o s e  of the present study was to 
determine the correlations between the state of 
carbohydrate metabolism and concentrations
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of apelin in the blood of patients with type 2 
diabetes mellitus with different phenotypes.
M a te ria ls  a n d  m e th o d s. A  total of 32 
patients with T2DM with different phenotypes 
(13 men, mean age 56,77 ± 1,79 years) were 
examined in the Department of Endocrinology 
at Kharkov Regional Hospital. The control group 
included 20 healthy individuals.
The following parameters were determined 
in the examined patients: body weight, height 
with subsequent calculation of body mass index 
(BMI) using the formula:
BMI (kg/m2) = weight (kg) / height (m2)
For the purpose of our research all patients 
were tested for serum glucose by glucose-oxidase 
Somogyi-Nelsone assay with a standard method; 
the level of glycosylated hemoglobin (HbA1c) 
was determined by kinetic method using «DAC- 
Spectro Med»; the level of immunoreactive 
insulin (IRI) -  ELISA method using «DRG» set 
of reagents. The evaluation of IR was performed 
according to homeostasis model assessment 
(HOMA) using the formula: HOMA-IR = IRI, 
mcU/ml * serum glucose, mmol/L / 22,5. The
content of apelin (C-Terminus peptide) was 
determined by immune-enzyme assay using 
«Raybiotech» set of reagents.
The examined patients were divided into 2 
groups that differed by the level of BMI: 1st group 
-  patients with T2DM with normal body weight 
(n=15), 2nd group -  patients with T2DM with 
increased body weight (n=17).
The correlation analysis was performed 
between all studied parameters according 
to their distribution law using Statistica 6.0 
licensed program.
During this clinical study we followed the 
safety precautions for the patients’ health, 
protection of their rights, human dignity 
and ethical standards in accordance with the 
principles of the Helsinki Declaration of Human 
Rights, the European Convention on Human 
Rights and Biomedicine, and applicable laws of 
Ukraine.
R e su lts . While comparing the received 
data, we found significant differences between 
selected groups not only in comparison with the 
control group, but also between the patients of 
the 1st and 2nd groups. The details are shown in 
the table.
Table
M e a n  v a lu e s  o f  in d ic e s  in  th e  s tu d ie d  g ro u p s





Age, years 42.55±0.73 55.07±2.89 57.5±2.3
Duration of T2DM, years - 12.13±1.54 10.1±2
Gender (male/female) 10/10 7/8 6/11
BMI, kg/m2 21.75±0.2 23.18±0.4* 29.9±0.7*/**
Serum glucose, mmol/l 4.98±0.06 8.68±0.53* 8.91±0.34*
HbA1c, % 5.83±0.07 7.24±0.16* 7.3±0.23*
IRI, mcU/ml 3.7±0.29 9.21±0 .47* 13.3±0.75*/**
HOMA-IR 0.82±0.06 3.67±0.33* 5.39±0.45*/**
Apelin, pg/ml 171±8.2 262.8±8.3* 296.7±9.2*/**
Note: *-significantly (p<0.05) differs from control group; * * -  significantly (p<0.05) differs from 1st group
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The revealed disorders of carbohydrate me­
tabolism demonstrated that the most difficult 
achievement of compensation of carbohydrate 
metabolism was observed in the 2nd group of 
patients (T2DM and overweight), despite an 
increase of carbohydrate derangements in all 
study groups of patients. The levels of apelin 
significantly increased in patients with T2DM 
and were higher in patients with increased body 
weight, which indicated the probable participa­
tion of this adypocytokine in the pathogenesis of 
T2DM and its progression in the presence of in­
creased body weight.
The presence of statistically higher levels of 
apelin in patients with IR and T2DM confirms 
the connection of this adypocytokine with the in­
sulin signaling pathway. In other words, insulin 
is able to control the secretion of apelin and to 
affect the metabolism due to indirect effects.
The largest increase of apelin was observed 
in patients with T2DM and overweight, which 
indicated a reliable involvement of this adypo- 
cytokine in the pathogenesis and progression of 
T2DM in the presence of increased body weight.
The close correlations between indices of car­
bohydrate metabolism (Fig. 1, Fig. 2) were found 
in patients with T2DM with different phenotype, 
and were particularly pronounced between all 
indices of carbohydrate metabolism in 2nd group 
with T2DM and overweight. As we can see, in­
creased body weight is an additional risk factor 
for development of disorders of carbohydrate 
metabolism, which affects the course and pro­
gression of pathological changes in T2DM.
The positive correlations between adypocyto­
kine apelin and indices of carbohydrate metabo­
lism were found in both groups of T2DM.
Figure 1. Correlations between BMI, apelin and indices 
o f carbohydrate metabolism in 1st group.
These relations were somewhat weaker or of these interactions was found in the group of
absent in the group of patients with T2DM patients with T2DM and overweight.
with normal body weight. The increasing trend
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Figure 2. Correlations between BMI, 
apelin and indices o f  carbohydrate metabolism in 2nd group
According to some authors, insulin is direct­
ly involved in the mechanisms of the regulation 
of apelin synthesis [4], namely controlling gene 
expression in adipocytes, which are responsible 
for the synthesis of apelin, as evidenced by the 
presence of significant positive correlation be­
tween levels of apelin and IRI in our research, 
with higher interdependence in patients with 
overweight. The given above data allow to con­
sider apelin as auxiliary diagnostic marker of IR.
The results of the study revealed an increased 
level of apelin in the serum of all patients with 
T2DM with different phenotypes, which is asso­
ciated with slower metabolism that negatively 
impacts the body as a whole, promotes the de­
velopment and deepening of late complications. 
It also is a factor of poor compensation of carbo­
hydrate metabolism, resulting in worsening and 
progression of T2DM.
C o n clu s io n s
1. The moderately increased levels of indi­
ces of carbohydrate metabolism and apelin were
found in patients with T2DM and normal body 
weight.
2. The significantly increased levels of ape- 
lin were found in patients with T2DM and over­
weight, while the levels of carbohydrate metab­
olism indices increased moderately. Probably, 
hyperapelinemia is an additional indicator of 
progression of metabolic changes and aggrava­
tion of IR in patients with T2DM with BMI over 
25.0 kg/m2.
3. The significant correlations between BMI, 
carbohydrate metabolism and apelin in both 
groups may indicate the interpotentiating role of 
these factors in the progression of T2DM, which 
deepens in patients with increased body weight.
P ro sp e c ts  fo r  fu tu r e  r e s e a r c h
The continuation of studies in this area 
should be aimed at establishing the other equally 
important factors of occurrence and progression 
of T2DM. It is necessary to continue the further 
research in this area, in particular when pheno­
type changes are present.
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